A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients. The new study will be presented at the European ...

The US FDA has granted AstraZeneca's (AZ) Brilinta a priority review for patients with a history of heart attack. The announcement is good news for AZ, which has identified Brilinta (ticagrelor ...

that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the US and Brilique in Europe), manufactured by AstraZeneca. Peter Doshi, senior editor at The BMJ ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor (Brilinta, AstraZeneca) and ticlopidine) are indicated in all STEMI cases unless urgent surgery is required. Clopidogrel can also be ...